Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG)
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Pulmonx Corp Common Stock (LUNG). This change, effective January 12, 2026, is due to an internal realignment under SEC Release No. 34-39538, which now requires certain Vanguard subsidiaries to report their holdings separately. The filing confirms Vanguard itself no longer holds beneficial ownership in Pulmonx.
If You Invested $1,000 in Pulmonx Corp (LUNG)
This article analyzes the historical performance of a $1,000 investment in Pulmonx Corp (LUNG), a medical technology company focused on COPD treatments. Over the past 10 years, an investment in LUNG would have significantly underperformed the S&P 500, resulting in a substantial loss. The article also provides detailed information about Pulmonx Corp's products, business model, and financial reporting.
LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pulmonx Corporation (LUNG) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights key events such as financial results, executive changes, and equity compensation structures while offering AI-powered summaries to help investors understand the documents quickly. Recent Form 4 filings detail insider share dispositions for tax withholding related to vested restricted stock units.
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther
Pulmonx Corp (NASDAQ: LUNG) stock has significantly declined year-to-date, trading near multi-year lows despite strong revenue beats and expanding adoption of its Zephyr Valve system for emphysema treatment. Analysts project substantial upside potential, with price targets implying a 367% increase, driven by the company's growth in the respiratory medtech market, particularly in Europe. The company is prioritizing R&D and sales expansion, with a clean balance sheet and sufficient liquidity, aiming for profitability inflection in the coming years.
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33)
Pulmonx (LUNG) reported its 2025 financial results, with revenue reaching $90.5 million, an 8.0% increase year-over-year due to higher procedure volumes. The company significantly narrowed its loss per share to $(1.33) from $(1.44) in the prior year, reflecting improvements in operating and net losses despite continued investments in commercial and clinical initiatives for its Zephyr Valve therapy. These results highlight growing adoption of their therapy both domestically and internationally, supported by ongoing R&D and clinical trials.
LUNG Technical Analysis & ETF Price Forecast
This article provides a technical analysis and price forecast for Pulmonx Corp (LUNG) ETF. It indicates a "Neutral" overall consensus based on technical sentiment, with specific moving average indicators suggesting a "Buy" signal for LUNG, despite the stock trading below its 60-day and 200-day moving averages. The analysis includes momentum indicators like RSI and MACD, support and resistance levels, and various other technical indicators.
Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable
Pulmonx Corporation (NASDAQ: LUNG), a medical technology company specializing in minimally invasive devices for severe emphysema, reported increased revenue of $90.5 million in 2025, up from $83.8 million in 2024, yet sustained a net loss of $54.0 million. The company continues to expand its Zephyr Valve sales, primarily through a direct sales force in the U.S., Europe, and Asia Pacific, while also developing the AeriSeal System to broaden its treatable patient population. Despite revenue growth and advanced product development, Pulmonx faces ongoing challenges including significant net losses, competition, regulatory hurdles, and reimbursement complexities, highlighting its need for additional capital to fund operations and achieve profitability.
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33)
Pulmonx reported 2025 revenue of $90.5 million, an 8.0% increase year-over-year, driven by higher procedure volumes. The company's loss per share improved to $(1.33) from $(1.44) as it continued to narrow operating and net losses while investing in commercial and clinical initiatives for its Zephyr Valve therapy. These results highlight increasing adoption among physicians and hospitals, along with ongoing R&D efforts.
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens
Pulmonx Corporation (LUNG) reported a decrease in revenue and a widening diluted loss per share for Q4 2025, with revenue down 4.9% year over year to $22.6 million and diluted loss per share at -$0.25. Insider trading activity showed significant sales, and institutional investors displayed mixed sentiment with both substantial additions and removals of shares. Analysts have issued "Buy" ratings and mixed price targets, with a median target of $5.0.
Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed
Soleus Capital Master Fund, L.P. and affiliated entities have reported a 6.5% beneficial ownership stake in Pulmonx Corporation (LUNG), totaling 2,665,100 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, calculated based on Pulmonx's outstanding shares as of October 31, 2025. The filing clarifies that while the shares are held directly by the Master Fund, other entities and Guy Levy disclaim beneficial ownership except for Section 13(d) obligations.
Pulmonx (NASDAQ: LUNG) adds $60M loan with Perceptive and issues warrants
Pulmonx Corporation has secured a new senior secured term loan facility of up to $60.0 million from Perceptive Credit Holdings V, LP, drawing an initial $40.0 million. The facility includes two additional $10.0 million tranches contingent on specific revenue targets being met by late 2027. In connection with this financing, Pulmonx issued warrants to Perceptive to purchase 1,000,000 common shares and fully repaid and terminated its previous credit facility with Canadian Imperial Bank of Commerce.
Earnings Preview For Pulmonx
Pulmonx (NASDAQ: LUNG) is set to announce its quarterly earnings on Wednesday, March 4, 2026, with analysts estimating an EPS of $-0.39. Despite beating EPS estimates last quarter, the stock price dropped, and over the past 52 weeks, shares are down 81.32%. The article also highlights Pulmonx's strong financial metrics, including a positive revenue growth trend, impressive net margin, and high returns on equity and assets, despite its stock performance.
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Corporation reported its Q4 and full-year 2025 earnings, with Q4 revenue at $22.6 million, a 5% decrease year-over-year, and full-year revenue up 8% to $90.5 million. CEO Glen French outlined a strategy to reaccelerate U.S. sales growth, advance clinical initiatives like the AeriSeal CONVERT II trial, and align spending towards profitability, addressing past operational and executional challenges. The company expects full-year 2026 revenue between $90 million and $92 million, anticipating a return to year-over-year growth in the U.S. and international markets by the second half of the year, alongside a significant reduction in cash burn.
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn
Pulmonx (LUNG) has secured a new senior secured term loan facility of up to $60 million with Perceptive Credit Holdings V, drawing $40 million initially and with access to two additional $10 million tranches. This new facility, maturing in March 2031, refinances their previous agreement with Canadian Imperial Bank of Commerce, providing expanded liquidity for growth. The company also issued warrants to Perceptive, including a 1,000,000-share warrant.
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, engaged in routine equity transactions. He sold 10,483 shares at $1.43 each to cover tax withholding obligations from vested Restricted Stock Units (RSUs) granted between 2022 and 2025. Concurrently, he received a new grant of 175,000 RSUs, which will vest quarterly over four years, bringing his directly held common stock position to 345,736 shares.
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M
Pulmonx (Nasdaq: LUNG) reported its Q4 and full-year 2025 financial results, with full-year revenue reaching $90.5 million, an 8% increase year-over-year. The company narrowed its net loss to $54.0 million for 2025 and refinanced its debt, securing a $60 million credit facility. Pulmonx provided guidance for 2026, projecting revenues between $90 million and $92 million, with an approximate 75% gross margin.
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections
Pulmonx Corporation (LUNG) reported a narrower-than-expected fourth-quarter loss of $0.25 per share, outperforming the estimated $0.39 loss and marking a 35.9% positive earnings surprise. The company also surpassed revenue projections, generating $22.6 million against an expectation of $22.25 million for the quarter ending December 2025. Despite these positive results, Pulmonx shares have declined about 30.8% year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Device for severe emphysema: Pulmonx secures up to $60M credit line
Pulmonx (Nasdaq: LUNG) has secured a five-year credit facility of up to $60 million with Perceptive Advisors, which includes an initial $40 million term loan to refinance existing debt and a potential additional $20 million by late 2027 based on revenue milestones. The agreement extends its debt maturity to 2031 with interest-only payments, aiming to strengthen its capital structure and allow the company to focus on commercial strategy and clinical programs for its minimally invasive treatments for severe emphysema. The market reacted moderately positively, with LUNG shares increasing by 4.86% after the announcement.
Earnings Preview For Pulmonx
Pulmonx (NASDAQ: LUNG) is scheduled to announce its quarterly earnings on March 4, 2026, with analysts expecting an EPS of $-0.39. The company's past performance shows that its stock price dropped after beating EPS estimates, and its shares are down 81.32% over the last 52 weeks. Financially, Pulmonx boasts a strong market capitalization, positive revenue trend with 5.47% growth, impressive net margin of -64.91%, strong ROE of -21.62%, and effective ROA of -9.78%, along with a low debt-to-equity ratio of 0.94.
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Pulmonx Corp (LUNG), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Key financial metrics such as gross margin (74.65%), operating margin (-66.94%), net margin (-64.91%), and Return on Equity (-73.73%) are presented. The company's market capitalization stands at $62.90M, and its gross margin is benchmarked against competitors NRXS (83.30%) and OM (42.36%).
Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Esperion (ESPR)
This article highlights bullish sentiments from financial analysts on several healthcare stocks, specifically Pulmonx (LUNG), Esperion (ESPR), and 908 Devices (MASS). Analysts reiterated Buy ratings for all three companies, providing price targets and discussing their individual performance metrics and market consensus. The report underscores the optimistic outlook within the Healthcare sector by these analysts.
LUNG Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Pulmonx Corp (LUNG), including income statements, balance sheets, and cash flow statements from SEC filings. It details key financial metrics, growth rates, and an assessment of financial health across various indicators such as profitability, leverage, liquidity, and cash flow quality. The analysis highlights the company's strong revenue growth and liquidity but points to ongoing unprofitability and low earnings quality.
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx Corporation (Nasdaq: LUNG) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026, after market close. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with a webcast available on their "Investors" section. Pulmonx focuses on minimally invasive treatments for COPD, including the FDA-approved Zephyr Endobronchial Valve.
Lung disease treatment firm Pulmonx sets March 4 date for 2025 results
Pulmonx (Nasdaq: LUNG) announced it will report its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a webcast available on the company’s investor website. The announcement led to a positive market reaction, with LUNG gaining 5.99% on the day the news was published.
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News
D. Boral Capital analyst Jason Kolbert has reaffirmed a Buy rating for Pulmonx (LUNG) with an unchanged price target of $14.00 USD. This decision reflects continued confidence in the medical technology company, which specializes in minimally invasive treatments for severe emphysema. Other analysts have made varying adjustments to their ratings and price targets over the past few months, with the average target price from six analysts currently at $5.75, suggesting a significant upside from its current price.
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx Corporation (Nasdaq: LUNG) announced it would release its financial results for the fourth quarter and full year of 2025 on March 4, 2026, after market close. The company's management will host a conference call to discuss these results, and a webcast will be available on its investor relations website. Pulmonx focuses on minimally invasive treatments for COPD, including its FDA-approved Zephyr Endobronchial Valve.
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out?
Pulmonx Corp (PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For current shareholders, the decision is whether to accept the cash offer or to hold out for a potentially higher bid, recognizing that the stock now functions as a merger arbitrage play rather than a growth stock. The acquisition offers a premium, but caps further upside, shifting the investment focus to the deal's closing probability and associated risks.
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out?
Pulmonx Corp (NASDAQ: PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For investors, the decision is now whether to accept the fixed cash offer or speculate on a higher bid, transforming the investment into a merger arbitrage situation. The deal, driven by scale, distribution synergies, and regulatory leverage, highlights a trend of innovative small-cap medtech companies exiting public markets through acquisition.
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts
Pulmonx Corporation (NASDAQ:LUNG) has received an average "Hold" recommendation from analysts, with a consensus 1-year price target of $6.81. The company, a commercial-stage medical device firm known for its Zephyr® endobronchial valve, has a market capitalization of $60.64 million and institutional ownership of about 91.04%. Several analysts recently updated their ratings and price targets, contributing to the "Hold" consensus.
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares?
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, has seen its stock price significantly decline over the past year due to reimbursement challenges and execution issues. The company's recent quarterly results showed revenue growth but also highlighted ongoing operating losses and the need for continued investment. Despite underlying clinical backing for its technology, the stock's future hinges on improved reimbursement, operational execution, and capital discipline, leaving investors at a crossroads between a potential turnaround and a value trap.
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares?
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, is experiencing significant stock price pressure, trading near its 52-week lows. The decline is attributed to a mix of reimbursement risks, execution challenges, and a broader market rotation away from smaller, unprofitable growth companies. Despite respectable revenue growth, investors remain cautious due to ongoing operating losses and a slow path to profitability, with analysts generally holding a "Hold" or "Market Perform" stance.
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
Pulmonx Corporation's shares have fallen by 29% in the last month, contributing to a 79% decline over the past year. The company's price-to-sales (P/S) ratio of 0.7x is significantly lower than the industry average, likely due to analyst forecasts predicting revenue growth of 17% annually, which is considerably less than the industry's projected 124% growth. This lower growth expectation seems to be the primary reason for investor pessimism and the depressed P/S ratio.
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
Pulmonx Corporation's shares have dropped 29% in the last month, contributing to a 79% decline over the past year. This poor performance has led to a low price-to-sales (P/S) ratio of 0.7x, significantly below the Medical Equipment industry average. Analysts forecast a 17% annual revenue growth for Pulmonx over the next three years, which is substantially lower than the industry's projected 124% growth, explaining the depressed P/S ratio.
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday
Pulmonx (NASDAQ:LUNG) is scheduled to announce its Q4 2025 earnings before market open on Wednesday, February 18th, with analysts forecasting a loss of ($0.39) per share. The company previously exceeded estimates in the prior quarter, reporting ($0.34) EPS against an expected ($0.40), but remains unprofitable with significant negative return on equity and net margins. Institutional investors hold a substantial portion of the company's stock, and its average analyst rating is "Hold" with a price target of $6.81.
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership
Pulmonx Corp. is preparing to release its Q4 2025 financial results in late February, with investors keen to assess if the company met its annual revenue targets of $89-90 million and how its new leadership team, including CEO Glen French and COO/CFO Derrick Sung, has performed. The market will specifically focus on revenue breakdown by geography, following a trend in Q3 2025 where international growth outpaced the U.S. market, and the overall trajectory of the medical technology firm.
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Pulmonx Corporation (NASDAQ:LUNG) has a healthy balance sheet, boasting net cash of US$39.4m against its debt of US$37.1m as of September 2025. While the company is unprofitable, with an EBIT loss and negative free cash flow, its strong cash position provides liquidity for growth. However, investors should remain cautious due to the company's lack of profitability and consider additional warning signs before making investment decisions.
Pulmonx Navigates Leadership Shift Amidst Mixed Financial Results
Pulmonx Corp (US7458481014) is experiencing significant price volatility following a mixed Q3 2025 earnings report and executive changes. The company saw 5% global revenue growth to $21.5 million, primarily from international markets, but reported a net loss of $14.0 million. Amidst a revised annual revenue outlook, Glen French returned as CEO and Derrick Sung became COO/CFO, while diverging insider transactions have raised questions.
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
Pulmonx Corporation's stock has seen a 26% increase over the last month, but this follows a 67% decline over the past year. Despite a low price-to-sales (P/S) ratio of 1x compared to an industry average of 3.5x, the company's future revenue growth forecast of 17% annually for the next three years is significantly lower than the industry's predicted 138% growth. This disparity in growth expectations is likely contributing to the suppressed P/S ratio, indicating that improved revenue performance is needed to justify a higher valuation.
Pulmonx CEO French sells $13.8k in LUNG stock
Pulmonx Corp CEO Glendon E. French III sold 8,805 common shares for approximately $13,823 to cover tax obligations related to vesting Restricted Stock Units (RSUs). French also acquired 1,200,000 RSUs and 800,000 Performance Stock Units, significantly increasing his holdings. The company, a micro-cap medical device firm, appears undervalued despite not being profitable in the last twelve months, holding more cash than debt but burning through reserves.
Pulmonx (Nasdaq: LUNG) issues 1,625,000-share inducement grants, incl. 1.6M RSUs/PSUs
Pulmonx Corporation announced that it granted equity awards totaling 1,625,000 shares to two new executives, including CFO Derrick Sung, under its 2025 Inducement Plan. The grants comprise 1,225,000 Restricted Stock Units (RSUs) and up to 400,000 Performance Stock Units (PSUs) for Sung, subject to both time-based and performance vesting conditions. These awards were made to incentivize the new hires and comply with Nasdaq Listing Rule 5635(c)(4).
Pulmonx Corporation Grants 1,625,000 Equity Awards as Part of 2025 Inducement Plan
Pulmonx Corporation has granted 1,625,000 equity awards, including restricted stock units (RSUs) and performance stock units (PSUs), to new hires under its 2025 Inducement Plan. Chief Financial Officer Derrick Sung received a significant portion of these awards, which are designed to attract and retain talent and are subject to vesting conditions based on time and performance. This move aims to align executive compensation with shareholder interests and support Pulmonx's strategic direction as a leader in minimally invasive treatments for chronic obstructive pulmonary disease.
Pulmonx stock rating reiterated at Buy by Stifel after 3Q results
Stifel has reiterated its Buy rating and $5.00 price target for Pulmonx Corp. (NASDAQ:LUNG) following the company's Q3 2025 earnings report. This rating comes despite lowered full-year sales guidance, as the company beat expectations for EPS and revenue, and new management aims for accelerated profitable growth. InvestingPro data also suggests the stock is currently undervalued with a significant revenue growth over the last year.
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Pulmonx (NASDAQ: LUNG) announced the reappointment of Glen French as President and CEO and Derrick Sung as COO and CFO, effective November 3, 2025, following the resignations of two executives. The company also reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million and rescheduled its Q3 earnings call to November 12, 2025. This leadership change aims to ensure stability and capitalize on growth opportunities in minimally invasive lung disease treatments.
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?
Pulmonx Corporation (LUNG) is considered one of the best stocks under $3, despite recent price target reductions by analysts. Lake Street and Stifel Nicolaus maintained a Buy rating, while Canaccord Genuity also kept a Buy rating with a higher price target. The company is a commercial-stage medical technology firm offering minimally invasive treatment for severe emphysema.
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?
Pulmonx Corporation (NASDAQ: LUNG) is highlighted as a potentially strong investment under $3, despite a recent price target reduction by Lake Street to $4 from $8 while maintaining a Buy rating. Analysts emphasize the company's attractive features, including proven Zephyr valves, significant market potential, and a new product pipeline. Other firms like Stifel Nicolaus and Canaccord Genuity also maintain Buy ratings with price targets of $5 and $6, respectively.
LUNG’s Surprise Revenue Surge: Key Factors
Pulmonx Corporation (NASDAQ: LUNG) experienced a significant stock surge of 34.62% following a Q3 revenue report of $21.5M, surpassing market estimates, and recent leadership changes. Despite encouraging revenue growth and a strong market response, the company faces profitability challenges with negative margins and return on assets. The article emphasizes observing both growth potential and financial pitfalls for LUNG's future trajectory.
Pulmonx brings back former CEO amid leadership shakeup
Pulmonx Corporation has reappointed Glen French as President and CEO, replacing Steve Williamson, and named former CFO Derrick Sung as COO and CFO. This leadership change comes as the company faces a nearly 75% stock drop over the past year and downward revised earnings expectations from analysts. Despite these challenges, Pulmonx reported an 18% year-over-year revenue growth in Q3 2025 and maintains a strong current ratio and net cash position, though profitability challenges persist.
Oct. 29, 2025: Pulmonx to Release Third Quarter Results; Webcast and Conference Call Available - Stock Titan
Pulmonx (Nasdaq: LUNG) announced it will release its third-quarter 2025 financial results on Wednesday, October 29, 2025, after market close. The company's management will host a conference call and webcast on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested participants need to register online to receive call-in details.
Jaeger™ and Pulmonx Announce Strategic Partnership to Integrate Data Qualification Capabilities into SentrySuite™
Jaeger™ Medical and Pulmonx Corporation have announced a strategic partnership to integrate advanced data qualification functionality into Jaeger's SentrySuite™ software platform. This collaboration aims to enhance the platform's ability to support consistent clinical decision-making by enabling healthcare providers to identify patients who may qualify for innovative treatments like the Zephyr Valve. The integration will streamline how clinicians interpret and act on respiratory diagnostic data, particularly for conditions like severe hyperinflation secondary to emphysema.
Pulmonx Corporation Announces Participation in Upcoming Investor Conferences | LUNG Stock News
Pulmonx Corporation announced its participation in the Wells Fargo Healthcare Conference and the Lake Street Best Ideas Growth Conference in September 2025. The company will present its innovative lung disease treatments, including the FDA-approved Zephyr® Endobronchial Valve. The article also details recent insider trading activity, hedge fund movements, and analyst ratings and price targets for LUNG stock.
